Gold, Silver, and Platinum Rally as Precious Metals Recover from Sharp Selloff 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Philippines Manufacturing PMI Hits Nine-Month High Despite Weak Confidence Outlook 
Gold Prices Stabilize in Asian Trade After Sharp Weekly Losses Amid Fed Uncertainty 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
U.S. Stock Futures Rise as Investors Eye Big Tech Earnings and AI Momentum 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
South Korea Factory Activity Hits 18-Month High as Export Demand Surges 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Trump Announces U.S.–India Trade Deal Cutting Tariffs, Boosting Markets and Energy Ties 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
